HERON THERAPEUTICS, INC. /DE/ (HRTX) Current Ratio
- Current ratio · latest quarter: Value 2.49×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.49× | Current assets / current liabilities. $229.84M ÷ $92.14M ≈ 2.49× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 229.84M USD | Assets, Current |
| Current obligations | 92.14M USD | Liabilities, Current |
| Cash and equivalents | 20.72M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 21.94M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 89.57M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 90.58M USD | Inventory, Net |
| Payables | 11.64M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $229.84M | $92.14M | $20.72M | $21.94M | $89.57M | $90.58M | $11.64M | (m) | 2.49× |
| 2026-03-31 | $228.98M | $90.52M | $26.12M | $18.67M | $83.69M | $92.54M | $8.97M | (m) | 2.53× |
| 2025-12-31 | $238.07M | $96.10M | $28.65M | $17.98M | $89.59M | $92.75M | $8.99M | (m) | 2.48× |
| 2025-09-30 | $229.40M | $89.71M | $43.07M | $12.42M | $81.05M | $70.03M | $12.02M | (m) | 2.56× |
| 2025-06-30 | $210.92M | $258.60M | $16.52M | $24.12M | $79.93M | $72.97M | $12.04M | (m) | 0.82× |
| 2025-03-31 | $212.84M | $88.56M | $19.27M | $31.41M | $78.74M | $56.93M | $12.33M | (m) | 2.40× |
| 2024-12-31 | $209.01M | $91.46M | $25.80M | $33.48M | $78.88M | $53.16M | $11.71M | (m) | 2.29× |
| 2024-09-30 | $195.19M | $85.54M | $25.74M | $45.15M | $67.04M | $45.95M | $10.19M | (m) | 2.28× |
| 2024-06-30 | $191.17M | $80.32M | $18.39M | $48.96M | $73.71M | $42.86M | $10.23M | (m) | 2.38× |
| 2024-03-31 | $185.90M | $75.38M | $20.45M | $51.07M | $65.32M | $42.47M | $837.00K | (m) | 2.47× |
| 2023-12-31 | $188.77M | $79.69M | $28.68M | $51.73M | $60.14M | $42.11M | $3.24M | (m) | 2.37× |
| 2023-09-30 | $193.98M | $79.75M | $34.86M | $42.55M | $63.80M | $42.01M | $1.86M | (m) | 2.43× |
| 2023-06-30 | $165.28M | $86.72M | $13.46M | $19.78M | $76.69M | $44.62M | $1.96M | (m) | 1.91× |
| 2023-03-31 | $178.16M | $77.90M | $27.09M | $32.93M | $51.45M | $52.06M | $4.07M | (m) | 2.29× |
| 2022-12-31 | $205.44M | $82.36M | $15.36M | $69.49M | $52.05M | $54.57M | $3.23M | (m) | 2.49× |
| 2022-09-30 | $223.80M | $93.88M | $50.44M | $71.31M | $42.19M | $52.24M | $6.55M | (m) | 2.38× |
| 2022-06-30 | $194.21M | $109.50M | $48.61M | $34.93M | $40.30M | $61.32M | $13.80M | (m) | 1.77× |
| 2022-03-31 | $222.59M | $93.00M | $56.91M | $55.00M | $41.10M | $56.47M | $8.23M | (m) | 2.39× |
| 2021-12-31 | $254.42M | $71.06M | $90.54M | $67.04M | $35.50M | $48.38M | $3.80M | (m) | 3.58× |
| 2021-09-30 | $315.05M | $72.30M | $159.57M | $43.25M | $43.09M | $41.50M | $5.88M | (m) | 4.36× |
| 2021-06-30 | $366.83M | $82.14M | $191.17M | $66.50M | $42.62M | $42.80M | $11.24M | (m) | 4.47× |
| 2021-03-31 | $272.29M | $100.92M | $59.74M | $106.73M | $38.52M | $42.63M | $1.69M | (m) | 2.70× |
| 2020-12-31 | $314.20M | $102.50M | $105.14M | $103.35M | $41.85M | $41.91M | $525.00K | (m) | 3.07× |
| 2020-09-30 | $351.00M | $97.58M | $95.14M | $163.00M | $33.65M | $42.75M | $12.07M | (m) | 3.60× |
| 2020-06-30 | $392.89M | $92.65M | $80.73M | $220.11M | $37.50M | $41.44M | $18.46M | (m) | 4.24× |
| 2020-03-31 | $438.45M | $96.77M | $103.28M | $253.06M | $34.81M | $34.85M | $11.56M | (m) | 4.53× |
| 2019-12-31 | $479.06M | $96.70M | $71.90M | $319.07M | $39.88M | $24.97M | $2.76M | (m) | 4.95× |
| 2019-09-30 | $364.15M | $96.74M | $60.11M | $196.17M | $66.95M | $24.17M | $1.63M | (m) | 3.76× |
| 2019-06-30 | $380.83M | $95.06M | $53.04M | $222.97M | $66.82M | $29.27M | $8.00M | (m) | 4.01× |
| 2019-03-31 | $406.20M | $92.26M | $23.46M | $265.78M | $74.01M | $31.42M | $10.81M | (m) | 4.40× |
| 2018-12-31 | $447.25M | $92.02M | $31.84M | $300.54M | $64.65M | $39.03M | $16.86M | (m) | 4.86× |
| 2018-09-30 | $460.06M | $64.09M | $53.93M | $310.87M | $53.63M | $31.41M | $9.64M | (m) | 7.18× |
| 2018-06-30 | $502.62M | $78.67M | $258.93M | $164.03M | $45.89M | $27.20M | $4.98M | (m) | 6.39× |
| 2018-03-31 | $176.56M | $91.18M | $46.58M | $67.36M | $37.71M | $19.42M | $11.46M | (m) | 1.94× |
| 2017-12-31 | $228.06M | $103.17M | $144.58M | $27.80M | $41.87M | $10.11M | $18.77M | (m) | 2.21× |
| 2017-09-30 | $112.59M | $53.14M | $65.52M | $8.49M | $28.85M | $5.17M | $5.34M | (m) | 2.12× |
| 2017-06-30 | $136.35M | $48.30M | $30.28M | $78.99M | $18.62M | $4.80M | $6.32M | (m) | 2.82× |
| 2017-03-31 | $183.62M | $37.40M | $83.51M | $81.70M | $10.33M | $4.64M | $4.48M | (m) | 4.91× |
| 2016-12-31 | $62.14M | $38.73M | $13.41M | $37.72M | $1.96M | $5.34M | $6.81M | (m) | 1.60× |
| 2016-09-30 | $93.97M | $30.93M | $45.64M | $43.28M | (m) | $1.98M | $6.09M | (m) | 3.04× |
| 2016-06-30 | $81.13M | $27.89M | $61.94M | $12.70M | (m) | $3.31M | $8.66M | (m) | 2.91× |
| 2016-03-31 | $108.20M | $19.17M | $68.02M | $32.39M | (m) | $2.74M | $6.86M | (m) | 5.64× |
| 2015-12-31 | $134.75M | $19.73M | $75.18M | $55.99M | (m) | (m) | $3.30M | (m) | 6.83× |
| 2015-09-30 | $155.00M | $16.45M | $152.99M | (m) | (m) | (m) | $2.73M | (m) | 9.42× |
| 2015-06-30 | $173.42M | $16.59M | $171.53M | (m) | (m) | (m) | $2.99M | (m) | 10.45× |
| 2015-03-31 | $56.50M | $11.63M | $55.56M | (m) | (m) | (m) | $2.38M | (m) | 4.86× |
| 2014-12-31 | $73.73M | $13.62M | $72.67M | $0.00 | (m) | (m) | $2.55M | (m) | 5.41× |
| 2014-09-30 | $89.24M | $11.27M | $86.21M | (m) | (m) | (m) | $1.48M | (m) | 7.92× |
| 2014-06-30 | $105.53M | $10.79M | $105.01M | (m) | (m) | (m) | $1.77M | (m) | 9.78× |
| 2014-03-31 | $59.74M | $7.38M | $57.48M | (m) | (m) | (m) | $3.60M | (m) | 8.09× |
| 2013-12-31 | $72.92M | $6.99M | $72.29M | (m) | (m) | (m) | $1.26M | (m) | 10.43× |
| 2013-09-30 | $23.36M | $5.50M | $22.60M | (m) | (m) | (m) | $2.25M | (m) | 4.25× |
| 2013-06-30 | $35.21M | $9.59M | $34.85M | (m) | (m) | (m) | $5.35M | (m) | 3.67× |
| 2013-03-31 | $46.15M | $7.60M | $45.72M | (m) | (m) | (m) | $3.83M | (m) | 6.08× |
| 2012-12-31 | $54.09M | $4.15M | $53.51M | (m) | (m) | (m) | $1.91M | (m) | 13.02× |
| 2012-09-30 | $60.40M | $4.24M | $60.05M | (m) | (m) | (m) | $1.76M | (m) | 14.23× |
| 2012-06-30 | $13.00M | $3.12M | $12.44M | (m) | (m) | (m) | $605.00K | (m) | 4.17× |
| 2012-03-31 | $13.75M | $3.36M | $13.44M | (m) | (m) | (m) | $890.00K | (m) | 4.09× |
| 2011-12-31 | $18.24M | $3.69M | $17.97M | (m) | (m) | (m) | $1.01M | (m) | 4.94× |
| 2011-09-30 | $21.32M | $2.54M | $21.02M | (m) | (m) | (m) | $433.00K | (m) | 8.39× |
| 2011-06-30 | $21.83M | $3.20M | $21.33M | (m) | (m) | (m) | $289.00K | (m) | 6.81× |
| 2010-12-31 | $2.50M | $1.56M | $2.11M | (m) | $110.00K | (m) | $159.00K | (m) | 1.60× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |